AAGH America Great Health (CE)

Crown Marketing, Inc. (OTCQB: CWNM) is pleased to announce that it is developing a tamper resistant oxycodone product based on its novel, patented Controlled Drug Delivery Device (CDDT).

Although great strides have been made to alleviate the abuse of narcotics, Crown believes they have developed a method to complement their Controlled Drug Delivery Device (CDDT) wherein tamper resistant features will further deter modifying opioids for abuse.

"We expect to file a provisional patent in the coming weeks," said C. Francis, Director of Business Development.

Opioids contribute to an estimated 15,000 U.S. deaths and more than 340,000 emergency department visits annually, according to the Centers for Disease Control and Prevention.

About Crown Marketing:

Crown Marketing's Controlled Drug Delivery Technology (CDDT) holds patents for a novel controlled-release technology, harnessing the principles of chaos theory along with precise mathematical formulas for precise and programmable diffusion delivery

The spectrum and reliability of pharmacokinetic profiles achievable with this technology is superior to currently marketed formulations. Its simple design allows for a high level of flexibility in matching chrono-therapeutic requirements. Cost-efficiencies in the commercial manufacturing process, when compared to other drug delivery technologies, may constitute its most important competitive advantage.

The objective of intelligent drug delivery design amounts to maximizing the percent of the time drug plasma levels are within the therapeutic range and avoiding patient exposure to potentially toxic (High) or sub-therapeutic (Low) levels.

Crown's cost-effective application of controlled delivery technologies will play a major role in the expansion of the pharmaceutical, OTC and nutraceuticals industry through our ability to improve on the performance of immediate release products in a manner tangible to manufacturers and consumers.

More information can be found at: www.crowncddt.com

This release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approvals for anticipated actions.

Contact: Charles Van Der Ross 347-491-0565